amphetamine has been researched along with Parkinson Disease, Secondary in 70 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 7.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 3.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| " Because prenylated proteins are avid methyl acceptors at the terminal carboxylic acid groups, 1 micromol S-farnesylcysteine (FC) analogs blocked the SAM-induced tremors in the experimental rats." | 3.70 | Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats. ( Charlton, CG; Lamango, NS, 2000) |
| " In the present study EGF is tested at a lower dosage starting administration at the time of lesion." | 1.29 | Effect of intracerebroventricular infusion of epidermal growth factor in rats hemitransected in the nigro-striatal pathway. ( Ventrella, LL, 1993) |
| "Riluzole was administered twice 15 min before, and 24 h after, the lesion." | 1.29 | Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. ( Barnéoud, P; Boireau, A; Doble, A; Dubédat, P; Mazadier, M; Miquet, JM; Parmentier, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (10.00) | 18.7374 |
| 1990's | 31 (44.29) | 18.2507 |
| 2000's | 21 (30.00) | 29.6817 |
| 2010's | 9 (12.86) | 24.3611 |
| 2020's | 2 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Pregeljc, D | 1 |
| Teodorescu-Perijoc, D | 1 |
| Vianello, R | 1 |
| Umek, N | 1 |
| Mavri, J | 1 |
| Elabi, OF | 1 |
| Cunha, JPMCM | 1 |
| Gaceb, A | 1 |
| Fex, M | 1 |
| Paul, G | 1 |
| Bhupal, PK | 1 |
| Anderson, KA | 1 |
| Shall, GP | 1 |
| Lynn, JD | 1 |
| Hoolsema, KS | 1 |
| Rossignol, J | 1 |
| Dunbar, GL | 1 |
| Sandstrom, MI | 1 |
| Loiodice, S | 1 |
| Wing Young, H | 1 |
| Rion, B | 1 |
| Méot, B | 1 |
| Montagne, P | 1 |
| Denibaud, AS | 1 |
| Viel, R | 1 |
| Drieu La Rochelle, C | 1 |
| Lappin, JM | 1 |
| Sara, GE | 1 |
| Perfeito, R | 1 |
| Cunha-Oliveira, T | 1 |
| Rego, AC | 1 |
| Ma, C | 1 |
| Pan, Y | 1 |
| Yang, Z | 1 |
| Meng, Z | 1 |
| Sun, R | 1 |
| Wang, T | 1 |
| Fei, Y | 1 |
| Fan, W | 1 |
| Anastasía, A | 1 |
| Torre, L | 1 |
| de Erausquin, GA | 1 |
| Mascó, DH | 1 |
| Tajiri, N | 1 |
| Yasuhara, T | 1 |
| Shingo, T | 1 |
| Kondo, A | 1 |
| Yuan, W | 1 |
| Kadota, T | 1 |
| Wang, F | 1 |
| Baba, T | 1 |
| Tayra, JT | 1 |
| Morimoto, T | 1 |
| Jing, M | 1 |
| Kikuchi, Y | 1 |
| Kuramoto, S | 1 |
| Agari, T | 1 |
| Miyoshi, Y | 1 |
| Fujino, H | 1 |
| Obata, F | 1 |
| Takeda, I | 1 |
| Furuta, T | 1 |
| Date, I | 2 |
| Gonzalez-Aparicio, R | 1 |
| Flores, JA | 1 |
| Fernandez-Espejo, E | 1 |
| Casas, S | 1 |
| García, S | 1 |
| Cabrera, R | 1 |
| Nanfaro, F | 1 |
| Escudero, C | 1 |
| Yunes, R | 1 |
| Chao, OY | 1 |
| Pum, ME | 1 |
| Li, JS | 1 |
| Huston, JP | 2 |
| Hao, G | 1 |
| Yao, Y | 1 |
| Wang, J | 3 |
| Zhang, L | 1 |
| Viroonchatapan, N | 1 |
| Wang, ZZ | 1 |
| Jollivet, C | 1 |
| Aubert-Pouessel, A | 1 |
| Clavreul, A | 1 |
| Venier-Julienne, MC | 1 |
| Montero-Menei, CN | 1 |
| Benoit, JP | 1 |
| Menei, P | 1 |
| Henderson, JM | 2 |
| Stanic, D | 1 |
| Tomas, D | 1 |
| Patch, J | 1 |
| Horne, MK | 1 |
| Bourke, D | 1 |
| Finkelstein, DI | 1 |
| Fjord-Larsen, L | 1 |
| Johansen, JL | 1 |
| Kusk, P | 1 |
| Tornøe, J | 1 |
| Grønborg, M | 1 |
| Rosenblad, C | 3 |
| Wahlberg, LU | 1 |
| Ericson, C | 1 |
| Georgievska, B | 2 |
| Lundberg, C | 1 |
| Ebert, AD | 1 |
| Beres, AJ | 1 |
| Barber, AE | 1 |
| Svendsen, CN | 2 |
| Kuan, WL | 1 |
| Zhao, JW | 1 |
| Barker, RA | 1 |
| van Dijk, A | 1 |
| Johnston, C | 1 |
| Allbutt, H | 1 |
| Kassiou, M | 1 |
| Henderson, J | 1 |
| Torres, EM | 2 |
| Dowd, E | 1 |
| Dunnett, SB | 3 |
| Fornaguera, J | 1 |
| Schwarting, RK | 1 |
| Boix, F | 1 |
| Furukawa, S | 1 |
| Ohmoto, T | 1 |
| Papa, SM | 1 |
| Engber, TM | 1 |
| Kask, AM | 1 |
| Chase, TN | 1 |
| Bankiewicz, KS | 3 |
| Plunkett, RJ | 1 |
| Oldfield, EH | 1 |
| Sakai, K | 1 |
| Gash, DM | 2 |
| Nikkhah, G | 2 |
| Cunningham, MG | 1 |
| Jödicke, A | 1 |
| Knappe, U | 1 |
| Björklund, A | 4 |
| Thomas, J | 1 |
| Takubo, H | 1 |
| Sheng, J | 1 |
| de Jesus, S | 1 |
| Kondoh, T | 1 |
| Blount, JP | 1 |
| Conrad, JA | 1 |
| Pundt, LL | 1 |
| Low, WC | 1 |
| Basso, MA | 1 |
| Strecker, RE | 1 |
| Evinger, C | 1 |
| Curran, EJ | 1 |
| Albin, RL | 1 |
| Becker, JB | 1 |
| Ventrella, LL | 1 |
| Yoshimoto, Y | 1 |
| Lin, Q | 1 |
| Collier, TJ | 1 |
| Frim, DM | 1 |
| Breakefield, XO | 1 |
| Bohn, MC | 1 |
| Barnéoud, P | 1 |
| Mazadier, M | 1 |
| Miquet, JM | 1 |
| Parmentier, S | 1 |
| Dubédat, P | 1 |
| Doble, A | 1 |
| Boireau, A | 1 |
| Winkler, C | 1 |
| Sauer, H | 2 |
| Lee, CS | 1 |
| Mendez, I | 3 |
| Sadi, D | 2 |
| Hong, M | 3 |
| Rozas, G | 1 |
| Labandeira García, JL | 1 |
| Bresjanac, M | 1 |
| Sagen, J | 1 |
| Seigel, G | 1 |
| Paino, CL | 1 |
| Kordower, J | 1 |
| Caldwell, MA | 1 |
| Shen, J | 1 |
| ter Borg, MG | 1 |
| Rosser, AE | 1 |
| Tyers, P | 1 |
| Karmiol, S | 1 |
| Van Keuren, KR | 1 |
| Stodgell, CJ | 1 |
| Schroeder, SR | 1 |
| Tessel, RE | 1 |
| Espejo, EF | 1 |
| Montoro, RJ | 1 |
| Armengol, JA | 1 |
| López-Barneo, J | 1 |
| Murer, MG | 1 |
| Dziewczapolski, G | 1 |
| Menalled, LB | 1 |
| García, MC | 1 |
| Agid, Y | 1 |
| Gershanik, O | 1 |
| Raisman-Vozari, R | 1 |
| Annett, LE | 1 |
| Chang, JW | 1 |
| Wachtel, SR | 1 |
| Young, D | 1 |
| Kang, UJ | 1 |
| Kirik, D | 2 |
| Devaux, B | 1 |
| Moffat, B | 1 |
| Phillips, HS | 1 |
| Dethy, S | 1 |
| Laute, MA | 1 |
| Damhaut, P | 1 |
| Goldman, S | 1 |
| Liu, HW | 1 |
| Kuang, YJ | 1 |
| Wu, JC | 1 |
| Ma, KH | 1 |
| Wang, SD | 1 |
| Liu, JC | 1 |
| Baker, KA | 2 |
| Lamango, NS | 1 |
| Charlton, CG | 1 |
| Höglinger, GU | 1 |
| Widmer, HR | 1 |
| Spenger, C | 1 |
| Meyer, M | 1 |
| Seiler, RW | 1 |
| Oertel, WH | 2 |
| Sautter, J | 1 |
| Chiang, Y | 1 |
| Morales, M | 1 |
| Zhou, FC | 1 |
| Borlongan, C | 1 |
| Hoffer, BJ | 1 |
| Wang, Y | 1 |
| Zhang, C | 1 |
| Steiner, JP | 1 |
| Hamilton, GS | 1 |
| Hicks, TP | 1 |
| Poulter, MO | 1 |
| Falkenstein, G | 1 |
| Rosenthal, C | 1 |
| Boules, M | 1 |
| Warrington, L | 1 |
| Fauq, A | 1 |
| McCormick, D | 1 |
| Richelson, E | 1 |
| Tsuboi, K | 1 |
| Shults, CW | 1 |
| Richfield, EK | 1 |
| Thiruchelvam, MJ | 1 |
| Cory-Slechta, DA | 1 |
| Wuertzer, C | 1 |
| Gainetdinov, RR | 1 |
| Caron, MG | 1 |
| Di Monte, DA | 1 |
| Federoff, HJ | 1 |
| Poirier, LJ | 1 |
| Wachtel, H | 1 |
| Kunow, M | 1 |
| Löschmann, PA | 1 |
| Frodl, EM | 1 |
| Kupsch, A | 1 |
| ten Bruggencate, G | 1 |
| Cadet, JL | 2 |
| Zhu, SM | 2 |
| Kujirai, K | 1 |
| Dollison, A | 1 |
| Angulo, J | 1 |
| Fahn, S | 1 |
| Miller, R | 1 |
| Beninger, RJ | 1 |
| Perese, DA | 1 |
| Ulman, J | 1 |
| Viola, J | 1 |
| Ewing, SE | 1 |
| Kamo, H | 1 |
| Kim, SU | 1 |
| McGeer, PL | 1 |
| Shin, DH | 1 |
| Klawans, HL | 1 |
| Goetz, C | 1 |
| Westheimer, R | 1 |
| Ungerstedt, U | 1 |
| Ljungberg, T | 1 |
| Steg, G | 1 |
| Arushanian, EB | 1 |
| Stoliarov, GV | 1 |
| Tolpyshev, BA | 1 |
| Arnold, OH | 1 |
| Collard, J | 1 |
| Deniker, P | 1 |
| Ginestet, D | 1 |
| Hippius, H | 1 |
| Itil, TM | 1 |
| Labhardt, F | 1 |
| Leeds, AA | 1 |
| Montanini, R | 1 |
| Morozov, G | 1 |
| Simon, P | 1 |
| Villeneuve, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
| Neuroactive Steroids in Acute Ischemic Stroke: Association With Cognitive, Functional and Neurological Outcomes.[NCT02914106] | 60 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| Changes in Plasma Cortisol, Brain-derived Neurotrophic Factor, and Nitrites in Patients With Acute Ischemic Stroke[NCT03242304] | 40 participants (Actual) | Observational | 2016-04-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for amphetamine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Psychostimulant use and the brain.
Topics: Amphetamine; Amphetamine-Related Disorders; Brain; Central Nervous System Stimulants; Cocaine; Cocai | 2019 |
Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Topics: alpha-Synuclein; Amphetamine; Dopaminergic Neurons; Humans; Illicit Drugs; Mitochondria; Oxidative S | 2013 |
On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamine; Animals; Apomorphine; Benza | 1991 |
Pathophysiology of schizophrenia and the striatum.
Topics: Adult; Amphetamine; Animals; Basal Ganglia; Catalepsy; Caudate Nucleus; Dihydroxyphenylalanine; Dopa | 1972 |
66 other studies available for amphetamine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
How Important Is the Use of Cocaine and Amphetamines in the Development of Parkinson Disease? A Computational Study.
Topics: Amphetamine; Animals; Cocaine; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drosophila mel | 2020 |
High-fat diet-induced diabetes leads to vascular alterations, pericyte reduction, and perivascular depletion of microglia in a 6-OHDA toxin model of Parkinson disease.
Topics: Amphetamine; Animals; Behavior, Animal; Blood-Brain Barrier; Corpus Striatum; Diabetes Mellitus, Typ | 2021 |
Behavioral and neurochemical responses derived from dopaminergic intrastriatal grafts in hemiparkinsonian rats engaged in a novel motor task.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Cell Differentiation; Corpus Striatum; Disease | 2018 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; | 2019 |
Pre-administration of BAX-inhibiting peptides decrease the loss of the nigral dopaminergic neurons in rats.
Topics: Amphetamine; Animals; Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Protein; Behavior, An | 2016 |
Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Analysis of Variance; Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Dop | 2009 |
Exercise exerts neuroprotective effects on Parkinson's disease model of rats.
Topics: Amphetamine; Animals; Ascorbic Acid; Behavior, Animal; Brain-Derived Neurotrophic Factor; Bromodeoxy | 2010 |
Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor β1 is enhanced after co-infusion in rats.
Topics: Algorithms; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Blotting, Wes | 2010 |
Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Cues; Depression; Dopamine Agonists; Male; | 2011 |
Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Cues; Depression; Dopamine Agonists; Male; | 2011 |
Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Cues; Depression; Dopamine Agonists; Male; | 2011 |
Progesterone prevents depression-like behavior in a model of Parkinson's disease induced by 6-hydroxydopamine in male rats.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Cues; Depression; Dopamine Agonists; Male; | 2011 |
The grid-walking test: assessment of sensorimotor deficits after moderate or severe dopamine depletion by 6-hydroxydopamine lesions in the dorsal striatum and medial forebrain bundle.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Up | 2012 |
Intrastriatal grafting of glomus cells ameliorates behavioral defects of Parkinsonian rats.
Topics: Amphetamine; Animals; Behavior, Animal; Carotid Body; Cell Differentiation; Cell Transplantation; Ce | 2002 |
Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease M | 2004 |
Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Callithrix; Cell Co | 2005 |
Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct.
Topics: Amphetamine; Analysis of Variance; Animals; Blotting, Western; Cell Count; Cell Line; Cloning, Molec | 2005 |
Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Astrocytes; Cell Count; Cell Transplantation; Cells, Cultured; Central Nervous | 2005 |
Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Cell Differentiation; Cells, Cultured; Central Nervous System Stimulants; Data | 2008 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nerv | 2008 |
Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Bridged-Ring Compounds; Disease Models | 2008 |
Recovery of functional deficits following early donor age ventral mesencephalic grafts in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Cell Survival; Central Nervous System Stimulants; Dopamine; | 2008 |
Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Functi | 1993 |
Increased nerve growth factor level in the distal stump of transected sciatic nerve in relation to aging and its application for neural grafting.
Topics: Adrenal Medulla; Aging; Amphetamine; Animals; Denervation; Disease Models, Animal; Male; Mice; Mice, | 1994 |
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.
Topics: Amphetamine; Animals; Apomorphine; Denervation; Immunohistochemistry; Levodopa; Male; Medial Forebra | 1994 |
Intrastriatal implantation of interleukin-1. Reduction of parkinsonism in rats by enhancing neuronal sprouting from residual dopaminergic neurons in the ventral tegmental area of the midbrain.
Topics: Amphetamine; Animals; Behavior, Animal; Dopamine; Drug Implants; Interleukin-1; Male; Neurons; Oxido | 1994 |
Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat.
Topics: Amphetamine; Animals; Apomorphine; Body Weight; Immunohistochemistry; Levodopa; Male; Motor Activity | 1994 |
Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Cell Transplantation; Dopamine; Female; Fetal Ti | 1994 |
A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization.
Topics: Amphetamine; Animals; Brain; Carbidopa; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Combination | 1994 |
Functional effects of transplanted human fetal ventral mesencephalic brain tissue from spontaneous abortions into a rodent model of Parkinson's disease.
Topics: Abortion, Spontaneous; Amphetamine; Animals; Biomarkers; Brain Tissue Transplantation; Female; Fetal | 1994 |
Midbrain 6-hydroxydopamine lesions modulate blink reflex excitability.
Topics: Amphetamine; Animals; Basal Ganglia; Blinking; Electric Stimulation; Electromyography; Habituation, | 1993 |
Adrenal medulla grafts in the hemiparkinsonian rat: profile of behavioral recovery predicts restoration of the symmetry between the two striata in measures of pre- and postsynaptic dopamine function.
Topics: Adrenal Medulla; Amphetamine; Animals; Apomorphine; Benzazepines; Cerebral Ventricles; Corpus Striat | 1993 |
Effect of intracerebroventricular infusion of epidermal growth factor in rats hemitransected in the nigro-striatal pathway.
Topics: Amphetamine; Animals; Biomarkers; Cell Count; Corpus Striatum; Dopamine; Epidermal Growth Factor; In | 1993 |
Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Astrocytes; Brain-Derived Neurotrophic Factor; Disease Models, An | 1995 |
Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Brain Chemistry; Ce | 1996 |
Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Antibody Specificity; Behavior, Animal; Cell Death; Disease Models, Animal; Do | 1996 |
Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants.
Topics: Amphetamine; Animals; Behavior, Animal; Brain Tissue Transplantation; Dopamine; Dopamine Agents; Fem | 1996 |
Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test.
Topics: Amphetamine; Animals; Apomorphine; Automation; Brain Tissue Transplantation; Female; Fetal Tissue Tr | 1997 |
Xenogeneic adrenal medulla graft rejection rather than survival leads to increased rat striatal tyrosine hydroxylase immunoreactivity.
Topics: Adrenal Medulla; Amphetamine; Animals; Cattle; Cell Transplantation; Corpus Striatum; Dopamine; Graf | 1997 |
Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Astrocytes; Brain Tissue Transplantation; Cell Count; Cell Differentiation; Ce | 1997 |
Fixed-ratio discrimination training as replacement therapy in Parkinson's disease: studies in a 6-hydroxydopamine-treated rat model.
Topics: Amphetamine; Animals; Apomorphine; Conditioning, Operant; Corpus Striatum; Discrimination Learning; | 1998 |
Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates.
Topics: Amphetamine; Animals; Behavior, Animal; Carotid Body; Corpus Striatum; Disease Models, Animal; Dopam | 1998 |
Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carrier Proteins; Disease | 1998 |
Behavioural effects of subthalamic nucleus lesions in the hemiparkinsonian marmoset (Callithrix jacchus).
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Dopamine Upta | 1998 |
Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions.
Topics: Adaptation, Physiological; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal | 1999 |
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Topics: Amphetamine; Animals; Antibodies; Apomorphine; Atrophy; Body Weight; Cerebral Ventricles; Corpus Str | 1999 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Ago | 1999 |
Intrastriatal transplantation of Sertoli cells may improve amphetamine-induced rotation and tyrosine hydroxylase immunoreactivity of the striatum in hemiparkinsonian rats.
Topics: Amphetamine; Animals; Corpus Striatum; Immunohistochemistry; Male; Parkinson Disease, Secondary; Rat | 1999 |
Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Cell Count; Cell Line; Corpus Striatum; Disease Models, Animal; Dopamine; Fema | 2000 |
Simultaneous intrastriatal and intranigral grafting (double grafts) in the rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Brain Tissue Transplantation; Central Nervous System Stimula | 2000 |
Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Chromatography, Gel; Cysteine; Freeze Dryin | 2000 |
Influence of time in culture and BDNF pretreatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavior, Animal; Brain Tissue Transplantation; Brain-Derived Neurotrophic Fac | 2001 |
Fetal intra-nigral ventral mesencephalon and kidney tissue bridge transplantation restores the nigrostriatal dopamine pathway in hemi-parkinsonian rats.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Dopamine; Dopamine Uptake Inhibitors; Fetal Tiss | 2001 |
Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
Topics: Amphetamine; Animals; Corpus Striatum; Dopamine; Female; Glial Cell Line-Derived Neurotrophic Factor | 2001 |
Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment.
Topics: Amphetamine; Animals; Behavior, Animal; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Do | 2001 |
Restorative plasticity of dopamine neuronal transplants depends on the degree of hemispheric dominance.
Topics: Amphetamine; Animals; Behavior, Animal; Brain Tissue Transplantation; Corpus Striatum; Disease Model | 2001 |
Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine | 2001 |
Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dose-R | 2002 |
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; alpha-Synuclein; Amphetamine; Animals; Behavior | 2002 |
Dopaminergic agonists in animal models of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Cats; Disease Models, Animal; Haplorhini; L | 1975 |
NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Apomorphine; Dopamin | 1992 |
Cryopreservation, survival and function of intrastriatal fetal mesencephalic grafts in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Cryopreservation; Female; Fetal | 1992 |
The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Biomarkers; Corpus Striatum; Immunohistochemistr | 1992 |
Implantation of genetically modified mesencephalic fetal cells into the rat striatum.
Topics: Amphetamine; Animals; Autoradiography; Brain Tissue Transplantation; Cell Line; Corpus Striatum; Fem | 1992 |
A 6-hydroxydopamine-induced selective parkinsonian rat model.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Disease Models, Animal; Functional Laterality; H | 1989 |
Functional recovery in a rat model of Parkinson's disease following transplantation of cultured human sympathetic neurons.
Topics: Amphetamine; Animals; Behavior, Animal; Catecholamines; Cells, Cultured; Corpus Striatum; Disease Mo | 1986 |
Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Drinking Behavior; Elect | 1974 |
[The effect of phenamine on medicinal parkinsonism and retardation of movement upon stimulation of the caudate nucleus (a clinico-experimental study)].
Topics: Amphetamine; Caudate Nucleus; Female; Haloperidol; Humans; Male; Parkinson Disease; Parkinson Diseas | 1970 |
Definition and classification of neuroleptics.
Topics: Amphetamine; Animals; Apomorphine; Autonomic Nervous System; Basal Ganglia Diseases; Behavior; Catal | 1970 |